Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel robust hepatitis C virus mouse efficacy model.

Qing Zhu1, Yoko Oei, Dirk B Mendel

  • 1Department of Pharmacology, Novartis Vaccines and Diagnostics, Chiron Corportion, Emeryville, CA 94608. Qing_zhu@chiron.com

Antimicrobial Agents and Chemotherapy
|September 29, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.

Cell host & microbe·2020
Same author

Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization.

NPJ vaccines·2020
Same author

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.

Lancet (London, England)·2019
Same author

Leonurine promotes neurite outgrowth and neurotrophic activity by modulating the GR/SGK1 signaling pathway in cultured PC12 cells.

Neuroreport·2019
Same author

Superamphiphobic Cu/CuO Micropillar Arrays with High Repellency Towards Liquids of Extremely High Viscosity and Low Surface Tension.

Scientific reports·2019
Same author

Mutational signatures and the genomic landscape of betel quid chewing-associated tongue carcinoma.

Cancer medicine·2019
Same journal

Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks.

Antimicrobial agents and chemotherapy·2026
Same journal

An Achilles' heel for methicillin-resistant <i>Staphylococcus aureus</i>? Re-evaluating β-lactam susceptibility of MRSA.

Antimicrobial agents and chemotherapy·2026
Same journal

Essential role of glycogen synthase kinase 3 in regulating growth, drug response, and infectivity in <i>Leishmania infantum</i>.

Antimicrobial agents and chemotherapy·2026
Same journal

<i>In vitro</i> antibacterial activity of gepotidacin in combination with other antimicrobial agents against <i>Neisseria gonorrhoeae</i> isolates.

Antimicrobial agents and chemotherapy·2026
Same journal

Development of domain-specific probes of <i>Plasmodium falciparum</i> heat shock protein 70-1.

Antimicrobial agents and chemotherapy·2026
Same journal

Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies.

Antimicrobial agents and chemotherapy·2026
See all related articles

Researchers developed a new mouse model to test hepatitis C virus (HCV) drugs. This model accurately tracks viral RNA replication, aiding in the discovery of effective antiviral therapies.

Area of Science:

  • Hepatology
  • Virology
  • Drug Discovery

Background:

  • Hepatitis C virus (HCV) drug development is hampered by the absence of effective small-animal models.
  • Accurate in vivo monitoring of viral replication is crucial for evaluating antiviral efficacy.

Purpose of the Study:

  • To develop and validate a reproducible xenograft mouse model for evaluating anti-HCV therapies.
  • To enable noninvasive, real-time monitoring of HCV RNA replication in vivo.

Main Methods:

  • Development of a xenograft mouse model using gamma-irradiated SCID mice engrafted with a luciferase-expressing HCV replicon cell line (T7-11).
  • In vivo monitoring of HCV RNA replication via noninvasive, whole-body imaging.
  • Validation using a protease inhibitor (BILN 2061) and interferon-alpha (IFN-alpha), assessing replication dynamics upon treatment and withdrawal.

Related Experiment Videos

Main Results:

  • The T7-11 xenograft model accurately reflects HCV RNA replication in vivo.
  • Both BILN 2061 and IFN-alpha demonstrated significant reduction in HCV RNA replication.
  • Treatment withdrawal led to a rebound in viral replication, mirroring human clinical outcomes.
  • Combination therapy of protease inhibitor and IFN-alpha showed superior efficacy compared to monotherapy.

Conclusions:

  • A robust and accessible xenograft mouse model for HCV has been established.
  • This model facilitates rapid in vivo evaluation of potential anti-HCV compounds.
  • The findings support the use of this model in drug discovery efforts for hepatitis C.